Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
Collagen-based biodegradable matrices for localized drug delivery More
An active ingredient purified from herbal material for the treatment of skin disorders and for wound-healing. More
Biotechnology Product for Wound Healing More
Our passive immunity patent portfolio concerns the local or topical administration of monoclonal or polyclonal antibody compositions in the prevention and treatment of infectious disease. More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
VEGF111, a novel naturally occurring isoform of human VEGF-A, was recently cloned. VEGF111 is active in terms of activation of VEGF receptors, induction of endothelial cells multiplication and stimulation of vascularisation in vitro and in vivo. As r More
These analogs were found to be potent inhibitors of IGF-1-mediated cell signaling and cancer cell growth, providing more binding specificity with less likelihood of significant toxic effects. More
Inherent Healing Accelerator for Improved Large Wound Healing More
Your selection
Browse By
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us